Effects of diabetes mellitus on amyotrophic lateral sclerosis: A systematic review

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Lekoubou, Alain ^a   Matsha, Tandi E ^b   Sobngwi, Eugene ^c   Kengne, Andre P ^d,e,f  

^a HÔPITAL NEUROLOGIQUE   (France)

^b CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 84899064072     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-171     Document Type: Review

References (27)

1. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose), Lancet 2011 378 31 40 10.1016/S0140- 6736(11)60679-X 21705069
2. The epidemiology of diabetic neuropathy. Shaw JE, Zimmet PZ, Diabetes Rev 1999 7 245 252
3. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert Group, Diabetes Care 2010 33 10 2285 2293 10.2337/dc10-1303 20876709
4. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Han T, Bai J, Liu W, Hu Y, Eur J Endocrinol 2012 167 4 465 471 10.1530/EJE-12-0555 22837391
5. Controversies and priorities in amyotrophic lateral sclerosis. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, Nicholson G, Ravits J, Shaw PJ, Swash M, Talbot K, Traynor BJ, Van den Berg LH, Veldink JH, Vucic S, Kiernan MC, Lancet Neurol 2013 12 3 310 322 10.1016/S1474-4422(13)70036-X 23415570
6. Amyotrophic lateral sclerosis: what role does environment play. Ahmed A, Wicklund MP, Neurol Clin 2011 29 3 689 711 10.1016/j.ncl.2011.06.001 21803219
7. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E, Harati Y, Strutt AM, York MK, Schulz PE, Amyotroph Lateral Scler 2010 11 6 542 548 10.3109/17482968.2010.482592 20500116
8. ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, Simpson E, Appel SH, York MK, Schulz PE, Eur J Neurol 2010 17 5 733 739 10.1111/j.1468-1331.2009.02923.x 20074230
9. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Pradat PF, Bruneteau G, Gordon PH, Dupuis L, Bonnefont-Rousselot D, Simon D, Salachas F, Corcia P, Frochot V, Lacorte JM, Jardel C, Coussieu C, Le Forestier N, Lacomblez L, Loeffler JP, Meininger V, Amyotroph Lateral Scler 2010 11 1-2 166 171 20184518
10. Respiratory control and oxidative phosphorylation in the denervated muscle of patients with amyotrophic lateral sclerosis Biochemical comparison with diabetes mellitus. Ionasescu V, Luca N, Vuia O, Popa V, Acta Neurol Scand 1968 44 4 440 456 10.1111/j.1600-0404.1968.tb05585.x 5687883
11. Glucose tolerance in amyotrophic lateral sclerosis. Harno K, Rissanen A, Palo J, Acta Neurol Scand 1984 70 6 451 455 6516795
12. Abnormal carbohydrate metabolism in amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam. Koerner DR, Diabetes 1976 25 11 1055 1065 10.2337/diab.25.11.1055 992226
13. Antecedent medical diseases in patients with amyotrophic lateral sclerosis. A population-based case-controlled study in Rochester, Minn, 1925 through 1987. Armon C, Kurland LT, O'Brien PC, Mulder DW, Arch Neurol 1991 48 3 283 286 10.1001/archneur.1991.00530150051017 2001186
14. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Chiò A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, Palmo A, Galletti R, Marinou K, Papetti L, Mora G, Neurology 2009 73 20 1681 1685 10.1212/WNL.0b013e3181c1df1e 19917991
15. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V, Neurology 2008 70 13 1004 1009 10.1212/01.wnl.0000285080.70324.27 18199832
16. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ, Am J Clin Nutr 1996 63 1 130 137 8604660
17. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrere B, Couratier P, Am J Clin Nutr 2001 74 3 328 334 11522556
18. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC, J Neurol 2011 258 4 613 617 10.1007/s00415-010-5805-z 21128082
19. Wildtype microglia extends survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, Siklos L, McKercher SR, Appel SH, Proc Natl Acad Sci U S A 2006 103 16021 16026 10.1073/pnas.0607423103 17043238
20. CD4+ T-cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH, Proc Natl Acad Sci U S A 2008 105 15558 15563 10.1073/pnas.0807419105 18809917
21. ALS: a disease of motor neurons and their nonneuronal neighbors. Boillée S, Vande Velde C, Cleveland DW, Neuron 2006 52 1 39 59 10.1016/j.neuron.2006.09.018 17015226
22. Diabetes mellitus and inflammation. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP, Curr Diab Rep 2013 13 3 435 444 10.1007/s11892-013-0375-y 23494755
23. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Hotamisligil GS, Shargill NS, Spiegelman BM, Science 1993 259 5091 87 91 10.1126/science.7678183 7678183
24. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. Luotola K, Pietilä A, Zeller T, Moilanen L, Kähönen M, Nieminen MS, Kesäniemi YA, Blankenberg S, Jula A, Perola M, Salomaa V, Health 2000 and FINRISK97 Studies, J Intern Med 2011 269 3 322 332 10.1111/j.1365-2796.2010. 02294.x 21205020
25. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Tanti JF, Ceppo F, Jager J, Berthou F, Front Endocrinol (Lausanne) 2012 3 181 23316186
26. Progression in ALS is not linear but is curvilinear. Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, Lacomblez L, Meininger V, J Neurol 2010 257 1713 1717 10.1007/s00415-010-5609-1 20532545
27. A proposed staging system for amyotrophic lateral sclerosis. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A, Brain 2012 135 847 852 10.1093/brain/awr351 22271664